Company: ARVN
Filing Date: 2025-01-10
Form Type: 8-K
Source: 0001655759-25-000004
Chunk: 0

Company: ARVINAS, INC.
Filing Date: 2025-01-10
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On January 10, 2025, Arvinas, Inc. (the “ Company”), announced updated guidance for the planned first- and second-line Phase 3 combination clinical trials for vepdegestrant in patients with locally advanced or metastatic estrogen receptor (“ ER”) positive (“ ER+”)/human epidermal growth factor receptor 2 (“ HER2”) negative (“ HER2-”; “ ER+/HER2-”) breast cancer, certain upcoming milestones anticipated in 2025 and provided a corporate update.

The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.